A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2024-12-17
- Target Recruit Count
- 295
- Registration Number
- NCT03933202
- Locations
- πΊπΈ
University of South Alabama, Mobile, Alabama, United States
πΊπΈRegina Berkovich MD PhD INC, West Hollywood, California, United States
πΊπΈColorado Springs Neurological Associates, PC - Neurology, Colorado Springs, Colorado, United States
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-08-21
- Target Recruit Count
- 70
- Registration Number
- NCT03840915
- Locations
- πΊπΈ
Compassionate Care Research Group Inc - Edinger Medical Group, Inc., Fountain Valley, California, United States
πΊπΈRCCA MD LLC - Bethesda, Bethesda, Maryland, United States
πΊπΈUniversity of Maryland - DUPLICATE/Pediatric Surgery, Baltimore, Maryland, United States
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-01-16
- Target Recruit Count
- 153
- Registration Number
- NCT03840902
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology, Houston, Texas, United States
πΊπΈLynn Cancer Institute Center, Boca Raton, Florida, United States
πΊπΈAmerican Health Network of Indiana, LLC, Indianapolis, Indiana, United States
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
- Conditions
- Interventions
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2023-10-25
- Target Recruit Count
- 159
- Registration Number
- NCT03833661
- Locations
- πΊπΈ
MD Anderson Cancer Center - Unit, Houston, Texas, United States
π―π΅Kindai University Hospital - Dept of Gastroenterology, Osakasayama-shi, Japan
πͺπΈHospital de la Santa Creu i Sant Pau, Barcelona, Spain
Avelumab Program Rollover Study
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 205
- Registration Number
- NCT03815643
- Locations
- πΊπΈ
Norwalk Hospital - The Whittingham Cancer Center, Norwalk, Connecticut, United States
πΊπΈHonorHealth Research Institute, Scottsdale, Arizona, United States
πΊπΈHighlands Oncology Group, Fayetteville, Arkansas, United States
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2023-03-21
- Target Recruit Count
- 19
- Registration Number
- NCT03770689
- Locations
- πΊπΈ
Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent, Columbus, Ohio, United States
πΊπΈUniversity of Colorado Cancer Center, Aurora, Colorado, United States
πΊπΈNorthwell Health, Inc, Great Neck, New York, United States
Study of Avelumab-M3814 Combinations
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2022-11-30
- Target Recruit Count
- 57
- Registration Number
- NCT03724890
- Locations
- πΊπΈ
H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States
πΊπΈThe University of Chicago Medical Center, Chicago, Illinois, United States
πΊπΈMount Sinai - PRIME (10707), Lake Success, New York, United States
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2020-11-13
- Target Recruit Count
- 3
- Registration Number
- NCT03704467
- Locations
- πΊπΈ
The Stamford Hospital, Stamford, Connecticut, United States
πΊπΈMarin Cancer Care, Inc., Greenbrae, California, United States
πΊπΈCovenant Health Care, Saginaw, Michigan, United States
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2024-08-13
- Target Recruit Count
- 304
- Registration Number
- NCT03631706
- Locations
- πΊπΈ
Cedars Sinai Medical Center - Inflammatory Bowel Disease Center (Clinic, Los Angeles, California, United States
πΊπΈDecatur Memorial Hospital - Clinical Research, Decatur, Illinois, United States
πΊπΈUPMC Cancer Center, Pittsburgh, Pennsylvania, United States
Tepotinib Hepatic Impairment Trial
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 18
- Registration Number
- NCT03546608
- Locations
- πΊπΈ
Qps Mra, Llc, Miami, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States